| Autor: |
de With M; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands.; Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam, The Netherlands., Knikman J; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Schellens JHM; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands., Cats A; Division of Medical Oncology, Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.; Leiden Network for Personalised Therapeutics (LNPT), Leiden, The Netherlands., Meulendijks D; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Medical Oncology, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Late Development Oncology, AstraZeneca, Cambridge, UK. |
Plný text